Physician profile
Robin Herb
NPI 1255639498
$1,739.00
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $912.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $346.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $301.94 | 2021-2022 | |
| Genzyme Corporation | $220.98 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $189.05 | 2021-2022 | |
| Mylan Specialty L.P. | $116.54 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $91.19 | 2022 | |
| Grifols USA, LLC | $82.46 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $67.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.97 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.33 | 2021-2022 | |
| Amgen INC. | $42.53 | 2022 | |
| Philips North America LLC | $32.41 | 2021-2022 | |
| United Therapeutics Corporation | $20.85 | 2022 | |
| Abbvie INC. | $15.79 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.87 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Herb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.